Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19
NCT ID: NCT04716569
Last Updated: 2021-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
150 participants
INTERVENTIONAL
2021-01-20
2021-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis
NCT02036229
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
NCT04476186
Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies
NCT05362513
Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts
NCT05429151
A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
NCT01066585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intranasal Ivermectin group
Ivermectin group Patients who will receive intranasal ivermectin
intranasal ivermectin spray
usage of ivermectin as intranasal spray for treating early covid patiens
Control group
patients who will receive regular protocol drugs
intranasal ivermectin spray
usage of ivermectin as intranasal spray for treating early covid patiens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intranasal ivermectin spray
usage of ivermectin as intranasal spray for treating early covid patiens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
South Valley University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zaky Aref
ass.professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zaky Aref
Qina, Qena Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Aref ZF, Bazeed SEES, Hassan MH, Hassan AS, Rashad A, Hassan RG, Abdelmaksoud AA. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19. Int J Nanomedicine. 2021 Jun 15;16:4063-4072. doi: 10.2147/IJN.S313093. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SVU MED CIT0 23 4 21 1 120
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.